Monocenter, double blinded, prospective, randomized placebo controlled study investigating prevention of major adverse cardiac events (MACEs) within 6 months by systemic treatment with everolimus after coronary intervention with bare metal stents in patients with significant coronary artery disease

Trial Profile

Monocenter, double blinded, prospective, randomized placebo controlled study investigating prevention of major adverse cardiac events (MACEs) within 6 months by systemic treatment with everolimus after coronary intervention with bare metal stents in patients with significant coronary artery disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery restenosis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 16 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top